The Advanced Practitioner’s Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2020

Predicting Drug Response in Acute Lymphoblastic Leukemia: Highlights From SOHO 2020

 Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, summarizes the session on the genomics of drug response in acute lymphoblastic leukemia presented by Jun J. Yang, PhD, of St. Jude’s Research Hospital, at ...

Immunotherapy for T-Cell ALL and T-NHL: Highlights From SOHO 2020

 In his keynote presentation, John DiPersio, MD, PhD, of Washington University, recipient of the SOHO 2020 Distinguished Lecturer Award, discussed immunotherapy for T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin lymphoma. All...

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020

 Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, highlights implications for advanced practitioners from the presentation at the 2020 SOHO Annual Meeting by Guillermo Garcia-Manero, MD, also from MD Ander...

Emerging Therapies in Myelofibrosis: Highlights From SOHO 2020

 Lisa Nodzon, PhD, ARNP, AOCNP®, of Moffitt Cancer Center, highlights new therapies in development for myelofibrosis that were discussed by Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the 2020 SOHO...

Updates on Therapeutic Advancements in Relapsed or Refractory Multiple Myeloma: Highlights From SOHO 2020

 Lisa Nodzon, PhD, APRN, AOCNP®, of Moffitt Cancer Center, discusses key points on the management of early relapse in multiple myeloma, a session presented at the 2020 SOHO Annual Meeting by Robert Z. Orlowski, MD, PhD, of The University...

Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020

 At the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, described the clinical implications of measuring minimal residual disease. Lisa Nodzon, Ph...

Integrating Novel Agents in Relapsed or Refractory Hodgkin Lymphoma: Highlights From SOHO 2020

 At the 2020 SOHO Annual Meeting, Alex F. Herrera, MD, of City of Hope, discussed the integration of novel agents into the management of patients with relapsed or refractory Hodgkin lymphoma. Kelly Valla, PharmD, BCOP, of Winship Cancer ...

Managing Relapsed Disease in Peripheral T-Cell Lymphoma: Highlights From SOHO 2020

 Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses takeaways from the session on relapsed T-cell lymphoma led by Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, at the 2020 SOHO Annua...

New CAR Designs: Highlights From SOHO 2020

 Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, considers exciting research on novel chimeric antigen receptor designs presented by Renier J. Brentjens, MD, PhD, of Memorial Sloan Kettering Cancer Center, at ...